Research programme: autologous T cell receptor cancer therapeutics - Kite Pharma/Netherlands Cancer InstituteAlternative Names: TCR cancer immunotherapy - Kite Pharma/ Netherlands Cancer Institute; TCR-based immuno-oncology therapeutics - Kite Pharma/Netherlands Cancer Institute
Latest Information Update: 20 Sep 2015
At a glance
- Originator Netherlands Cancer Institute
- Mechanism of Action Cell replacements; T-cell receptor gene modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours